Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Jansen, Andrea ^a   Szekat, Christiane ^a   Schröder, Wiebke ^b   Wolz, Christiane ^b   Goerke, Christiane ^b   Lee, Jean C ^c   Türck, Michael ^a   Bierbaum, Gabriele ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; COMPLEMENTARY RNA; POLYSACCHARIDE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOSYNTHESIS; GENOME ANALYSIS; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; TRANSCRIPTOMICS;

ANTI-BACTERIAL AGENTS; BACTERIAL CAPSULES; GENE EXPRESSION; GENE SILENCING; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UP-REGULATION; VANCOMYCIN;

STAPHYLOCOCCUS AUREUS;

EID: 84875144599     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-65     Document Type: Article

References (62)

1. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K, J Antimicrob Chemother 1998 42 199 209 10.1093/jac/42.2.199 9738837
2. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Cui L, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y, Antimicrob Agents Chemother 2006 50 428 438 10.1128/AAC.50.2.428-438.2006 16436693
3. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, J Clin Microbiol 2003 41 5 14 10.1128/JCM.41.1.5-14.2003 12517819
4. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Reipert A, Ehlert K, Kast T, Bierbaum G, Antimicrob Agents Chemother 2003 47 568 576 10.1128/AAC.47.2.568-576.2003 12543661
5. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. Sieradzki K, Tomasz A, J Bacteriol 1997 179 2557 2566 9098053
6. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus. Sieradzki K, Tomasz A, Antimicrob Agents Chemother 2006 50 527 533 10.1128/AAC.50.2.527-533.2006 16436706
7. Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50. Utaida S, Pfeltz RF, Jayaswal RK, Wilkinson BJ, Antimicrob Agents Chemother 2006 50 1541 1545 10.1128/AAC.50.4.1541-1545.2006 16569879
8. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K, Antimicrob Agents Chemother 2000 44 2276 2285 10.1128/AAC.44.9.2276-2285.2000 10952568
9. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML, Clin Microbiol Rev 2010 23 99 139 10.1128/CMR.00042-09 20065327
10. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Cui L, Lian JQ, Neoh HM, Reyes E, Hiramatsu K, Antimicrob Agents Chemother 2005 49 3404 3413 10.1128/AAC.49.8. 3404-3413.2005 16048954
11. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Kuroda M, Kuwahara-Arai K, Hiramatsu K, Biochem Biophys Res Commun 2000 269 485 490 10.1006/bbrc.2000.2277 10708580
12. Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. Mongodin E, Finan J, Climo MW, Rosato A, Gill S, Archer GL, J Bacteriol 2003 185 4638 4643 10.1128/JB.185.15.4638-4643.2003 12867477
13. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Cui L, Neoh HM, Shoji M, Hiramatsu K, Antimicrob Agents Chemother 2009 53 1231 1234 10.1128/AAC.01173-08 19124662
14. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, PLoS Pathog 2011 7 1002359 10.1371/journal.ppat.1002359 22102812
15. Tracking changes in the vraSR and graSR two component regulatory systems during the development and loss of vancomycin non-susceptibility in a clinical isolate. Doddangoudar VC, Boost MV, Tsang DN, O'Donoghue MM, Clin Microbiol Infect 2011 17 1268 1272 10.1111/j.1469-0691.2011.03463.x 21375655
16. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, PLoS Pathog 2012 8 1002505 10.1371/journal.ppat.1002505 22319446
17. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC, Antimicrob Agents Chemother 2012 56 5845 5851 10.1128/AAC.01139-12 22948864
18. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K, Antimicrob Agents Chemother 2008 52 45 53 10.1128/AAC.00534-07 17954695
19. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Meehl M, Herbert S, Götz F, Cheung A, Antimicrob Agents Chemother 2007 51 2679 2689 10.1128/AAC.00209-07 17502406
20. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, Antimicrob Agents Chemother 2010 54 5222 5233 10.1128/AAC.00437-10 20837752
21. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. Watanabe Y, Cui L, Katayama Y, Kozue K, Hiramatsu K, J Clin Microbiol 2011 49 2680 2684 10.1128/JCM.02144-10 21525224
22. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K, Antimicrob Agents Chemother 2011 55 4188 4195 10.1128/AAC.00398-11 21746940
23. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Passalacqua KD, Satola SW, Crispell EK, Read TD, Antimicrob Agents Chemother 2012 56 5212 5223 10.1128/AAC.05770-11 22850507
24. The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus. Jousselin A, Renzoni A, Andrey DO, Monod A, Lew DP, Kelley WL, Antimicrob Agents Chemother 2012 56 3629 3640 10.1128/AAC.06264-11 22526301
25. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Antimicrob Agents Chemother 2011 55 3870 3881 10.1128/AAC.01563-10 21628539
26. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Maki H, McCallum N, Bischoff M, Wada A, Berger-Bächi B, Antimicrob Agents Chemother 2004 48 1953 1959 10.1128/AAC.48.6.1953-1959.2004 15155184
27. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Jansen A, Türck M, Szekat C, Nagel M, Clever I, Bierbaum G, Int J Med Microbiol 2007 297 205 215 10.1016/j.ijmm.2007.02.002 17418637
28. Southern hybridization analysis of the mecA deletion from methicillin-resistant Staphylococcus aureus. Wada A, Katayama Y, Hiramatsu K, Yokota T, Biochem Biophys Res Commun 1991 176 1319 1325 10.1016/0006-291X(91) 90430-F 2039513
29. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC, J Antimicrob Chemother 1997 40 135 136 10.1093/jac/40.1.135 9249217
30. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Forsyth RA, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, Trawick JD, Mol Microbiol 2002 43 1387 1400 10.1046/j.1365-2958.2002.02832.x 11952893
31. Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Herbert S, Ziebandt AK, Ohlsen K, Schäfer T, Hecker M, Albrecht D, Infect Immun 2010 78 2877 2889 10.1128/IAI.00088-10 20212089
32. Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Sass P, Bierbaum G, Int J Med Microbiol 2009 299 313 322 10.1016/j.ijmm.2008.10.005 19138560
33. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Kreiswirth BN, Löfdahl S, Betley MJ, O'Reilly M, Schlievert PM, Bergdoll MS, Nature 1983 305 709 712 10.1038/305709a0 6226876
34. Genetic analysis of the cap5 locus of Staphylococcus aureus. Wann ER, Dassy B, Fournier JM, Foster TJ, FEMS Microbiol Lett 1999 170 97 103 10.1111/j.1574-6968.1999.tb13360.x 9919657
35. Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Pöhlmann-Dietze P, Ulrich M, Kiser KB, Döring G, Lee JC, Fournier JM, Infect Immun 2000 68 4865 4871 10.1128/IAI.68.9.4865-4871.2000 10948098
36. Improved method for electroporation of Staphylococcus aureus. Schenk S, Laddaga RA, FEMS Microb Lett 1992 94 133 138 10.1111/j.1574-6968.1992.tb05302.x
37. A novel site on the chromosome of Staphylococcus aureus influencing the level of methicillin resistance: genetic mapping. Berger-Bächi B, Kohler ML, FEMS Microbiol Lett 1983 20 305 309
38. A vector for systematic gene inactivation in Bacillus subtilis. Vagner V, Dervyn E, Ehrlich SD, Microbiology 1998 144 3097 3104 10.1099/00221287-144-11- 3097 9846745
39. Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus. Lee JC, Michon F, Perez NE, Hopkins CA, Pier GB, Infect Immun 1987 55 2191 2197 3623697
40. Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection. Cook J, Hepler R, Pancari G, Kuklin N, Fan H, Wang XM, Hum Vaccin 2009 5 254 263 10.4161/hv.5.4.6765 18787395
41. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Tzianabos AO, Wang JY, Lee JC, Proc Natl Acad Sci USA 2001 98 9365 9370 10.1073/pnas.161175598 11470905
42. Staphylococcus aureus strain designation by agr and cap polymorphism typing and delineation of agr diversification by sequence analysis. Goerke C, Esser S, Kümmel M, Wolz C, Int J Med Microbiol 2005 295 67 75 10.1016/j.ijmm.2005.01.004 15969467
43. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Bierbaum G, Fuchs K, Lenz W, Szekat C, Sahl HG, Eur J Clin Microbiol Infect Dis 1999 18 691 696 10.1007/s100960050380 10584894
44. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A, J Clin Microbiol 2003 41 1687 1693 10.1128/JCM.41.4.1687-1693.2003 12682161
45. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. McAleese F, Wu SW, Sieradzki K, Dunman P, Murphy E, Projan S, J Bacteriol 2006 188 1120 1133 10.1128/JB.188.3.1120-1133.2006 16428416
46. Characterization of the Staphylococcus aureus CidR regulon: elucidation of a novel role for acetoin metabolism in cell death and lysis. Yang SJ, Dunman PM, Projan SJ, Bayles KW, Mol Microbiol 2006 60 458 468 10.1111/j.1365-2958. 2006.05105.x 16573694
47. Effect of mild acid on gene expression in Staphylococcus aureus. Weinrick B, Dunman PM, McAleese F, Murphy E, Projan SJ, Fang Y, J Bacteriol 2004 186 8407 8423 10.1128/JB.186.24.8407-8423.2004 15576791
48. Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Nelson JL, Rice KC, Slater SR, Fox PM, Archer GL, Bayles KW, Antimicrob Agents Chemother 2007 51 616 622 10.1128/AAC.01057-06 17130298
49. Regulation of cytoplasmic pH in bacteria. Booth IR, Microbiol Rev 1985 49 359 378 3912654
50. Functional characterization of the sigmaB-dependent yabJ-spoVG operon in Staphylococcus aureus: role in methicillin and glycopeptide resistance. Schulthess B, Meier S, Homerova D, Goerke C, Wolz C, Kormanec J, Antimicrob Agents Chemother 2009 53 1832 1839 10.1128/AAC.01255-08 19223635
51. The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Sau S, Bhasin N, Wann ER, Lee JC, Foster TJ, Lee CY, Microbiology 1997 143 2395 2405 10.1099/00221287-143-7-2395 9245821
52. Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. Luong T, Sau S, Gomez M, Lee JC, Lee CY, Infect Immun 2002 70 444 450 10.1128/IAI.70.2.444-450.2002 11796569
53. Staphylococcus aureus capsular polysaccharides. O'Riordan K, Lee JC, Clin Microbiol Rev 2004 17 218 234 10.1128/CMR.17.1.218-234.2004 14726462
54. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA, Infect Immun 2004 72 7107 7114 10.1128/IAI.72.12.7107-7114.2004 15557634
55. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Llobet E, Tomas JM, Bengoechea JA, Microbiology 2008 154 3877 3886 10.1099/mic.0.2008/022301-0 19047754
56. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Boyle-Vavra S, Berke SK, Lee JC, Daum RS, Antimicrob Agents Chemother 2000 44 272 277 10.1128/AAC.44.2.272-277.2000 10639349
57. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. Howden BP, Smith DJ, Mansell A, Johnson PD, Ward PB, Stinear TP, BMC Microbiol 2008 8 39 10.1186/1471-2180-8-39 18304359
58. Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus. Ouyang S, Sau S, Lee CY, J Bacteriol 1999 181 2492 2500 10198014
59. CodY in Staphylococcus aureus: a regulatory link between metabolism and virulence gene expression. Pohl K, Francois P, Stenz L, Schlink F, Geiger T, Herbert S, J Bacteriol 2009 191 2953 2963 10.1128/JB.01492-08 19251851
60. UDP-acetyl-mannosamine dehydrogenase is an endogenous protein substrate of Staphylococcus aureus protein-tyrosine kinase activity. Soulat D, Grangeasse C, Vaganay E, Cozzone AJ, Duclos B, J Mol Microbiol Biotechnol 2007 13 45 54 10.1159/000103596 17693712
61. Genetic systems in staphylococci. Novick RP, Methods Enzymol 1991 204 587 636 1658572
62. Susceptibility of capsular Staphylococcus aureus strains to some antibiotics, triclosan and cationic biocides. Seaman P, Day M, Russell AD, Ochs D, J Antimicrob Chemother 2004 54 696 698 10.1093/jac/dkh382 15282235